Janssen Biotech

Company

Last mentioned: Mar 10, 2026

Timeline

  1. FY 2025 Earnings

    Legend Biotech reports full-year financial results and 2026 strategic outlook.

  2. Pipeline Update

    Initial Phase 1 data released for solid tumor candidates in neuroendocrine carcinoma.

  3. Manufacturing Milestone

    Ghent facility reaches full operational capacity for commercial production.

  4. Label Expansion

    Carvykti receives FDA approval for earlier lines of multiple myeloma treatment.

Stories mentioning Janssen Biotech 1

market-trends Neutral

Legend Biotech Reports 2025 Results as Carvykti Scales in Early-Line Myeloma

Legend Biotech (LEGN) has released its full-year 2025 financial results, showcasing significant revenue growth driven by the continued commercial expansion of its lead CAR-T therapy, Carvykti. The company highlighted major manufacturing milestones and a strategic pivot toward solid tumor indications following a year of intensive market penetration in earlier lines of multiple myeloma treatment.

2 sources